No Data
No Data
Cautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market Skepticism
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position
Inception Fertility Announces the Acceptance of 36 Abstracts to Be Presented at the 2024 ASRM Scientific Congress
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns upgrades $Prelude Therapeutics(PRLD.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.2%